ABSI — Absci Corp

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1672688 ·
Last close
$7.58
Market Cap
$1.31B
52W High
$12.55
52W Low
$2.24
ADV30
4,259,299
Next earnings
2026-11-12
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 304,000 — -34,994,000 -33,300,000 239,574,000 13,359,000 20,897,000
Jun 2026 318,000 — -34,158,000 -33,210,000 268,917,000 107,865,000 22,786,000
Mar 2026 215,000 — -30,846,000 -29,599,000 195,593,000 8,627,000 23,622,000
Dec 2025 650,000 — -36,142,000 -29,562,000 216,297,000 20,025,000 26,848,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-112,520,000
Investing CF
$-16,073,000
Financing CF
$116,140,000
CapEx
$-1,002,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-720,893,000
Inventory
—
Receivables
$1,000,000
ST Investments
$160,370,000
EBIT TTM
$-125,706,000
Pretax Income TTM
$-125,757,000
Interest Exp TTM
$51,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,487,000
EBITDA
$-124,500,000
Free Cash Flow
$-50,902,876
Enterprise Value
$1,289,261,056
Total Cash
$173,728,992
Total Debt
$3,288,000
Shares Out
172,745,810
Trailing EPS
$-0.79
Book Value
$1.27
ROE
-58.6%
ROA
-34.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,800,000 -125,418,000 -115,183,000 216,297,000 26,848,000 189,449,000 -92,925,000
Dec 2024 4,534,000 -108,888,000 -103,106,000 213,608,000 34,475,000 179,133,000 -72,402,000
Dec 2023 5,718,000 -94,180,000 -110,566,000 217,298,000 41,122,000 176,176,000 -64,636,000
Dec 2022 5,747,000 -106,750,000 -104,904,000 321,008,000 46,594,000 274,414,000 -81,339,000

TTM Snapshot

Revenues TTM
$1,561,000
NetIncome TTM
$-121,077,000
OpCashFlow TTM
—
Assets (Latest)
$268,917,000
Forward EPS
$-0.70

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $8.18 · call volume: 1,320 · put volume: 270
Expected Move to 2026-12-18: ±$3.97 (48.53%) — implied range $4.21 – $12.15 · ATM straddle on $8.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NTLA Intellia Therapeutics, Inc. $1.37B $9.78 —
CLDX Celldex Therapeutics, Inc. $2.20B $28.04 —
OABI OmniAb, Inc. $736.59M $5.05 —
NEOG NEOGEN CORP $2.38B $10.90 —
QDEL QuidelOrtho Corp $677.21M $9.87 —

News headlines (Yahoo Finance, 1h cache)

Absci Corp. (ABSI) Gets Downgraded. Here’s How Much
2026-11-17 01:43 · Yahoo
Absci (ABSI) Advances ABS 201 Plans, Is The 43% Discount Justified?
2026-11-13 23:18 · Yahoo
Absci Corp (ABSI) Q3 2026 Earnings Call Highlights: ABS-201 Momentum Builds as Cash Runway ...
2026-11-12 23:08 · Yahoo
Absci Corporation Q3 2026 Earnings Call Summary
2026-11-12 17:58 · Yahoo
Absci (ABSI) Q3 2026 Earnings Call Transcript
2026-11-12 17:14 · Yahoo
Absci Q3 Earnings Call Highlights
2026-11-12 16:15 · Yahoo
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 12:35 · Yahoo
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
2026-11-12 12:05 · Yahoo
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
2026-11-12 12:00 · Yahoo
Absci (ABSI) Stock Could Be Overvalued Given Its Book Value Gap
2026-11-06 22:16 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.